97 related articles for article (PubMed ID: 30243588)
1. Growth inhibition of human ovarian carcinoma by a novel AvidinOX-anchored biotinylated camptothecin derivative.
Minenkova O; Vesci L; De Santis R; Santapaola D; Cincinelli R; Musso L; Dallavalle S; Giannini G
Bioorg Med Chem Lett; 2018 Nov; 28(20):3312-3314. PubMed ID: 30243588
[TBL] [Abstract][Full Text] [Related]
2. AvidinOX-anchored biotinylated trastuzumab and pertuzumab induce down-modulation of ErbB2 and tumor cell death at concentrations order of magnitude lower than not-anchored antibodies.
Milazzo FM; Anastasi AM; Chiapparino C; Rosi A; Leoni B; Vesci L; Petronzelli F; De Santis R
Oncotarget; 2017 Apr; 8(14):22590-22605. PubMed ID: 28186982
[TBL] [Abstract][Full Text] [Related]
3. Preclinical pharmacology and safety of a novel avidin derivative for tissue-targeted delivery of radiolabelled biotin.
Petronzelli F; Anastasi AM; Pelliccia A; Santapaola D; Albertoni C; Rosi A; Leoni B; Ferrari LE; Paganelli G; Gramiccioli G; Pesce D; Alfano AM; Stasi MA; De Santis R
Basic Clin Pharmacol Toxicol; 2011 Sep; 109(3):145-55. PubMed ID: 21426491
[TBL] [Abstract][Full Text] [Related]
4. AvidinOX™ for tissue targeted delivery of biotinylated cells.
Nucera E; Nicoletti C; Chiapparino C; Pacello ML; D'Alessio V; Musarò A; De Santis R
Int J Immunopathol Pharmacol; 2012; 25(1):239-46. PubMed ID: 22507336
[TBL] [Abstract][Full Text] [Related]
5. Intra-tumor AvidinOX allows efficacy of low dose systemic biotinylated Cetuximab in a model of head and neck cancer.
Vesci L; Milazzo FM; Anastasi AM; Petronzelli F; Chiapparino C; Carollo V; Roscilli G; Marra E; Luberto L; Aurisicchio L; Pacello ML; Spagnoli LG; De Santis R
Oncotarget; 2016 Jan; 7(1):914-28. PubMed ID: 26575422
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of aerosol therapy of lung cancer correlates with EGFR paralysis induced by AvidinOX-anchored biotinylated Cetuximab.
De Santis R; Rosi A; Anastasi AM; Chiapparino C; Albertoni C; Leoni B; Pelliccia A; Santapaola D; Carollo V; Marra E; Aurisicchio L; Arseni B; Pacello ML; Palmieri G; Battella S; Petronzelli F; Milazzo FM
Oncotarget; 2014 Oct; 5(19):9239-55. PubMed ID: 25238453
[TBL] [Abstract][Full Text] [Related]
7. Radionuclide Therapy of Unresectable Tumors with AvidinOX and (90)Y-biotinDOTA: Tongue Cancer Paradigm.
Albertoni C; Leoni B; Rosi A; D'Alessio V; Carollo V; Spagnoli LG; van Echteld C; De Santis R
Cancer Biother Radiopharm; 2015 Sep; 30(7):291-8. PubMed ID: 26167947
[TBL] [Abstract][Full Text] [Related]
8. Chemical linkage to injected tissues is a distinctive property of oxidized avidin.
De Santis R; Anastasi AM; Pelliccia A; Rosi A; Albertoni C; Verdoliva A; Petronzelli F; D'Alessio V; Serani S; Nuzzolo CA
PLoS One; 2011; 6(6):e21075. PubMed ID: 21701578
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic efficacy of intra-tumor AvidinOX and low systemic dose biotinylated cetuximab, with and without cisplatin, in an orthotopic model of head and neck cancer.
Vesci L; Carollo V; Rosi A; De Santis R
Oncol Lett; 2019 Mar; 17(3):3529-3536. PubMed ID: 30867794
[TBL] [Abstract][Full Text] [Related]
10. Characterization of therapeutic protein AvidinOX by an integrated analytical approach.
Giannini G; Alekseeva A; Naggi A; Salvini L; Tei L; De Santis R
Anal Bioanal Chem; 2018 Jan; 410(2):553-564. PubMed ID: 29167933
[TBL] [Abstract][Full Text] [Related]
11. AvidinOX for highly efficient tissue-pretargeted radionuclide therapy.
De Santis R; Leoni B; Rosi A; Albertoni C; Forni G; Cojoca R; Iezzi M; Musiani P; Paganelli G; Chinol M; Carminati P
Cancer Biother Radiopharm; 2010 Apr; 25(2):143-8. PubMed ID: 20423226
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of the novel camptothecin gimatecan against orthotopic and metastatic human tumor xenograft models.
De Cesare M; Pratesi G; Veneroni S; Bergottini R; Zunino F
Clin Cancer Res; 2004 Nov; 10(21):7357-64. PubMed ID: 15534112
[TBL] [Abstract][Full Text] [Related]
13. The avidin-biotin complex (ABC) method and other avidin-biotin binding methods.
Bratthauer GL
Methods Mol Biol; 2010; 588():257-70. PubMed ID: 20012837
[TBL] [Abstract][Full Text] [Related]
14. A novel intravascular drug delivery method using endothelial biotinylation and avidin-biotin binding.
Hoya K; Guterman LR; Miskolczi L; Hopkins LN
Drug Deliv; 2001; 8(4):215-22. PubMed ID: 11757779
[TBL] [Abstract][Full Text] [Related]
15. Tumor pretargeting: role of avidin/streptavidin on monoclonal antibody internalization.
Casalini P; Luison E; Ménard S; Colnaghi MI; Paganelli G; Canevari S
J Nucl Med; 1997 Sep; 38(9):1378-81. PubMed ID: 9293791
[TBL] [Abstract][Full Text] [Related]
16. Tumor targeting with biotinylated tumor necrosis factor alpha: structure-activity relationships and mechanism of action on avidin pretargeted tumor cells.
Corti A; Gasparri A; Sacchi A; Curnis F; Sangregorio R; Colombo B; Siccardi AG; Magni F
Cancer Res; 1998 Sep; 58(17):3866-72. PubMed ID: 9731496
[TBL] [Abstract][Full Text] [Related]
17. Use of avidin/biotin-liposome system for enhanced peritoneal drug delivery in an ovarian cancer model.
Zavaleta CL; Phillips WT; Soundararajan A; Goins BA
Int J Pharm; 2007 Jun; 337(1-2):316-28. PubMed ID: 17276633
[TBL] [Abstract][Full Text] [Related]
18. In vitro &in vivo targeting behaviors of biotinylated Pluronic F127/poly(lactic acid) nanoparticles through biotin-avidin interaction.
Xiong XY; Guo L; Gong YC; Li ZL; Li YP; Liu ZY; Zhou M
Eur J Pharm Sci; 2012 Aug; 46(5):537-44. PubMed ID: 22538053
[TBL] [Abstract][Full Text] [Related]
19. Gimatecan exerts potent antitumor activity against gastric cancer in vitro and in vivo via AKT and MAPK signaling pathways.
Chen Z; Liu Z; Huang W; Li Z; Zou J; Wang J; Lin X; Li B; Chen D; Hu Y; Ji J; Gao J; Shen L
J Transl Med; 2017 Dec; 15(1):253. PubMed ID: 29237470
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of ovarian cancer growth by a tumor-targeting peptide that binds eukaryotic translation initiation factor 4E.
Ko SY; Guo H; Barengo N; Naora H
Clin Cancer Res; 2009 Jul; 15(13):4336-47. PubMed ID: 19458052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
